Novorapid 100 U/mL Solution for injection.
PDF Leaflet Revision Date: 05 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above.
Dosage (summary)
Individualized; typically 0.5-1.0 units/kg/day, with 50-70% from NovoRapid.
Onset of Action / Duration
Onset: 10-20 mins, Duration: 3-5 hours
Special Populations
- Paediatric population
- Elderly patients
Pregnancy & Breastfeeding
Safe in pregnancy; does not cross placenta. Safe during breastfeeding.
Key Drug Interactions
- Oral hypoglycemics may reduce insulin needs
- Beta-blockers may mask hypoglycemia symptoms
Contraindications
- Hypersensitivity to insulin aspart
- Hypoglycaemia
Common side effects
- Hypoglycaemia
- Injection site reactions
- Lipodystrophy
Counselling Points
- Administer immediately before meals
- Rotate injection sites
- Carry sugar for hypoglycaemia
Serious warnings
- Risk of severe hypoglycaemia
- Monitor for hyperglycaemia in Type 1 diabetes
Important Disclaimer
The Novorapid 100 U/mL Solution for injection. professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
